Therapeutics News and Research

RSS

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics AG and The Leukemia & Lymphoma Society today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM13, a novel tetravalent bispecific antibody directed against human CD30 and CD16A in Hodgkin Lymphoma patients for whom currently available treatments have failed.

16 Sep 2013

Relmada Therapeutics collaborates with the Malvern Consulting Group

Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that has signed a collaboration agreement with the Malvern Consulting Group as clinical and regulatory advisor.

16 Sep 2013

Researchers report first experimental evidence that supports theory of buckyball

Researchers at the Virginia Tech Carilion Research Institute have reported the first experimental evidence that supports the theory that a soccer ball-shaped nanoparticle commonly called a buckyball is the result of a breakdown of larger structures rather than being built atom-by-atom from the ground up.

16 Sep 2013

MJFF Forms Research Tool Development Consortium For Parkinson's

...

13 Sep 2013

Research findings bring scientists one step closer to preventing HIV infections

In a long-awaited finding, a team of Chinese and US scientists has determined the high-resolution atomic structure of a cell-surface receptor that most strains of HIV use to get into human immune cells. The researchers also showed where maraviroc, an HIV drug, attaches to cells and blocks HIV’s entry.

13 Sep 2013

Cell Therapeutics agrees to sell 15,000 shares of Series 18 Preferred Stock to Quogue Capital

Cell Therapeutics, Inc. today announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering").

13 Sep 2013

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Four new pre-clinical drug development projects at the National Institutes of Health will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers.

13 Sep 2013

Scottsdale Healthcare, TGen initiate Thunder God vine clinical trial in pancreatic cancer patients

Taking a page from Chinese herbal medicine, Scottsdale Healthcare and the Translational Genomics Research Institute today initiated the first-in-human clinical trial for pancreatic cancer patients using a compound derived from a plant known as "Thunder God vine."

13 Sep 2013

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.

12 Sep 2013

Elevated miR-200 boosts survival of lung, ovarian, renal, triple-negative breast cancer patients

A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor's ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center report today in Nature Communications.

12 Sep 2013

Breckenridge acquires Cypress Pharmaceutical product assets from Pernix Therapeutics

Breckenridge Pharmaceutical, Inc. announced today that it has completed its acquisition of certain Cypress Pharmaceutical, Inc. product assets from Pernix Therapeutics. The assets include 11 Abbreviated New Drug Applications filed with the FDA, certain ANDAs in various stages of development, as well as 6 already-approved and marketed products.

12 Sep 2013

MicroBiome Therapeutics' NM504 eliminates diarrhea caused by metformin in type 2 diabetes patient

MicroBiome Therapeutics LLC, a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.

11 Sep 2013

Developing Analytical Techniques for Biotherapeutics

News-Medical talks to Dr. Lewis about the development of analytical equipment for a new era of drug development that goes beyond small molecule synthesis.

From Malvern Panalytical 11 Sep 2013

Biogen Idec, Amicus Launch Parkinson's Collaboration

...

10 Sep 2013

Bayer, Broad On Five-Year Mission To Search For Novel Cancer Therapeutics

...

10 Sep 2013

Relmada Therapeutics reports positive results from pivotal pharmacokinetic study of LevoCap ER

Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.

10 Sep 2013

Study suggests expanded screening in younger women greatly reduces breast cancer mortality rate

A new analysis published online Sept. 9 in Cancer confirms the need for greater use of annual mammography in women ages 40-49 as recommended by the American Cancer Society, American Congress of Obstetricians and Gynecologists (ACOG), American College of Radiology and Society of Breast Imaging for all women 40 and older.

10 Sep 2013

Penn’s ITMAT symposium addresses topics of direct relevance to translational science

The Institute for Translational Medicine and Therapeutics' 7th Annual International Symposium (ITMAT) symposium, Harnessing the Paradox: Personalization and the Science of Scale, to be held in October 2013, will address topics of direct relevance to translational science.

7 Sep 2013

Researchers find key mechanism behind Alzheimer's disease

Alzheimer's disease affects more than 26 million people worldwide. It is predicted to skyrocket as boomers age-nearly 106 million people are projected to have the disease by 2050.

7 Sep 2013

Clinical trial of Grafix for treatment of chronic diabetic foot ulcers accepted for presentation at SAWC

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix® for the treatment of chronic diabetic foot ulcers has been accepted for podium presentation at the upcoming Symposium on Advanced Wound Care (SAWC) in Las Vegas on Friday, September 27, 2013.

7 Sep 2013

Therapeutics News and Research

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Relmada Therapeutics collaborates with the Malvern Consulting Group

Researchers report first experimental evidence that supports theory of buckyball

MJFF Forms Research Tool Development Consortium For Parkinson's

Research findings bring scientists one step closer to preventing HIV infections

Cell Therapeutics agrees to sell 15,000 shares of Series 18 Preferred Stock to Quogue Capital

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Scottsdale Healthcare, TGen initiate Thunder God vine clinical trial in pancreatic cancer patients

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

Elevated miR-200 boosts survival of lung, ovarian, renal, triple-negative breast cancer patients

Breckenridge acquires Cypress Pharmaceutical product assets from Pernix Therapeutics

MicroBiome Therapeutics' NM504 eliminates diarrhea caused by metformin in type 2 diabetes patient

Developing Analytical Techniques for Biotherapeutics

Biogen Idec, Amicus Launch Parkinson's Collaboration

Bayer, Broad On Five-Year Mission To Search For Novel Cancer Therapeutics

Relmada Therapeutics reports positive results from pivotal pharmacokinetic study of LevoCap ER

Study suggests expanded screening in younger women greatly reduces breast cancer mortality rate

Penn’s ITMAT symposium addresses topics of direct relevance to translational science

Researchers find key mechanism behind Alzheimer's disease

Clinical trial of Grafix for treatment of chronic diabetic foot ulcers accepted for presentation at SAWC

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest News